MCID: DFF036
MIFTS: 53

Differentiated Thyroid Carcinoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases

Aliases & Classifications for Differentiated Thyroid Carcinoma

MalaCards integrated aliases for Differentiated Thyroid Carcinoma:

Name: Differentiated Thyroid Carcinoma 59 17
Papillary or Follicular Thyroid Carcinoma 59
Differentiated Thyroid Gland Carcinoma 72
Well-Differentiated Thyroid Carcinoma 59

Characteristics:

Orphanet epidemiological data:

59
differentiated thyroid carcinoma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe); Age of onset: Adult;

Classifications:

Orphanet: 59  
Rare endocrine diseases


External Ids:

ICD10 via Orphanet 34 C73
UMLS via Orphanet 73 C0238463
Orphanet 59 ORPHA146
UMLS 72 C1337013

Summaries for Differentiated Thyroid Carcinoma

MalaCards based summary : Differentiated Thyroid Carcinoma, also known as papillary or follicular thyroid carcinoma, is related to thyroid cancer, nonmedullary, 1 and papillary carcinoma. An important gene associated with Differentiated Thyroid Carcinoma is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are Nanog in Mammalian ESC Pluripotency and Phospholipase-C Pathway. The drugs Hormones and Hormone Antagonists have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and bone, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Differentiated Thyroid Carcinoma

Diseases related to Differentiated Thyroid Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 216)
# Related Disease Score Top Affiliating Genes
1 thyroid cancer, nonmedullary, 1 32.0 NCOA4 GAS8-AS1 CCDC6 BRAF
2 papillary carcinoma 31.6 RET PAX8 NCOA4 BRAF
3 thyroid gland disease 30.8 RET PAX8 NCOA4
4 thyroid cancer, nonmedullary, 2 30.8 RET PPARG PAX8 NRAS HRAS BRAF
5 thyroid carcinoma, familial medullary 30.4 RET NTRK1 KRAS
6 renal cell carcinoma, papillary, 1 30.2 PAX8 NRAS HRAS BRAF
7 lung cancer susceptibility 3 30.1 NRAS KRAS HRAS BRAF ALK
8 thyroid carcinoma 11.3
9 urachal adenocarcinoma 10.8 KRAS BRAF
10 thyroid gland papillary carcinoma 10.7
11 sigmoid neoplasm 10.7 KRAS HRAS
12 giant congenital nevus 10.7 NRAS HRAS
13 thyroid gland follicular carcinoma 10.7
14 hyperplastic polyposis syndrome 10.7 KRAS BRAF
15 pulmonic stenosis 10.7 KRAS HRAS BRAF
16 cardiofaciocutaneous syndrome 1 10.7 KRAS HRAS BRAF
17 apocrine adenoma 10.7 KRAS HRAS
18 adult mesoblastic nephroma 10.6 NTRK3 ETV6
19 lung adenoid cystic carcinoma 10.6 KRAS HRAS ALK
20 spitz nevus 10.6 HRAS BRAF
21 mucinous lung adenocarcinoma 10.6 KRAS HRAS ALK
22 hypothyroidism 10.6
23 colorectal adenocarcinoma 10.6 KRAS HRAS BRAF
24 ovarian serous cystadenocarcinoma 10.6 NRAS HRAS BRAF
25 paronychia 10.6 KRAS HRAS
26 schimmelpenning-feuerstein-mims syndrome 10.6 NRAS KRAS HRAS
27 hyperthyroidism 10.6
28 goiter 10.6
29 adult fibrosarcoma 10.6 NTRK3 HRAS ETV6
30 melanoma, uveal 10.6 NRAS EIF1AX BRAF
31 periampullary adenoma 10.5 KRAS HRAS
32 acneiform dermatitis 10.5 NRAS KRAS HRAS
33 hypoparathyroidism 10.5
34 core binding factor acute myeloid leukemia 10.5 NRAS KRAS HRAS
35 liver angiosarcoma 10.5 NRAS KRAS HRAS
36 cellular congenital mesoblastic nephroma 10.5 NTRK3 NRAS ETV6
37 respiratory system cancer 10.5 KRAS HRAS ALK
38 congenital mesoblastic nephroma 10.5 NTRK3 NRAS ETV6
39 thyroiditis 10.5
40 pediatric fibrosarcoma 10.5 NTRK3 NTRK1 ETV6
41 leukemia, chronic lymphocytic 2 10.5 NRAS KRAS HRAS BRAF
42 leukemia, chronic lymphocytic 10.5 NRAS KRAS HRAS BRAF
43 nevus, epidermal 10.5 NRAS KRAS HRAS
44 congenital fibrosarcoma 10.5 NTRK3 NTRK1 ETV6
45 lung squamous cell carcinoma 10.5 KRAS HRAS BRAF ALK
46 autonomic nervous system neoplasm 10.5 NTRK1 NRAS ALK
47 ovary epithelial cancer 10.5 PAX8 KRAS HRAS
48 peripheral nervous system neoplasm 10.5 NTRK1 NRAS ALK
49 malignant ovarian surface epithelial-stromal neoplasm 10.5 PAX8 KRAS HRAS
50 respiratory system disease 10.5 KRAS HRAS ALK

Graphical network of the top 20 diseases related to Differentiated Thyroid Carcinoma:



Diseases related to Differentiated Thyroid Carcinoma

Symptoms & Phenotypes for Differentiated Thyroid Carcinoma

GenomeRNAi Phenotypes related to Differentiated Thyroid Carcinoma according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.65 HRAS KRAS BRAF
2 Decreased viability GR00106-A-0 10.65 KRAS
3 Decreased viability GR00221-A-1 10.65 HRAS KRAS PPARG RET ALK NRAS
4 Decreased viability GR00221-A-2 10.65 HRAS KRAS NTRK3 PPARG RET
5 Decreased viability GR00221-A-3 10.65 HRAS PPARG NTRK1 NRAS
6 Decreased viability GR00221-A-4 10.65 NTRK3 PPARG RET BRAF ALK
7 Decreased viability GR00231-A 10.65 RET
8 Decreased viability GR00301-A 10.65 KRAS RET BRAF NTRK1
9 Decreased viability GR00381-A-1 10.65 KRAS BRAF
10 Decreased viability GR00402-S-2 10.65 HRAS KRAS NTRK3 PPARG RET BRAF
11 Decreased cell migration GR00055-A-1 9.55 ALK BRAF HRAS KRAS NTRK1
12 Reduced mammosphere formation GR00396-S 9.28 BRAF CCDC6 EIF1AX ETV6 HRAS KRAS

MGI Mouse Phenotypes related to Differentiated Thyroid Carcinoma:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.37 ALK BRAF ETV6 GOLGA5 HRAS KRAS
2 behavior/neurological MP:0005386 10.36 ALK BRAF GOLGA5 HRAS KRAS NRAS
3 mortality/aging MP:0010768 10.33 ALK BRAF ERC1 ETV6 GOLGA5 HRAS
4 cardiovascular system MP:0005385 10.27 BRAF ETV6 HRAS KRAS LPAR4 NRAS
5 homeostasis/metabolism MP:0005376 10.27 ALK BRAF ERC1 ETV6 HRAS KRAS
6 embryo MP:0005380 10.25 BRAF ETV6 GOLGA5 KRAS LPAR4 NDUFA13
7 endocrine/exocrine gland MP:0005379 10.19 ALK BRAF ETV6 HRAS KRAS NRAS
8 integument MP:0010771 10.13 ALK BRAF ETV6 HRAS KRAS LPAR4
9 craniofacial MP:0005382 10.11 BRAF GOLGA5 HRAS KRAS LPAR4 NRAS
10 digestive/alimentary MP:0005381 10.1 BRAF ETV6 GOLGA5 HRAS KRAS NRAS
11 nervous system MP:0003631 10.1 ALK BRAF HRAS KRAS NTRK1 NTRK3
12 no phenotypic analysis MP:0003012 10.07 ERC1 ETV6 HRAS KRAS NRAS NTRK1
13 normal MP:0002873 10.06 BRAF ERC1 ETV6 HRAS KRAS NRAS
14 neoplasm MP:0002006 10.03 ALK BRAF ETV6 HRAS KRAS NRAS
15 hearing/vestibular/ear MP:0005377 9.99 BRAF KRAS NTRK1 NTRK3 PAX8 PPARG
16 respiratory system MP:0005388 9.7 ALK BRAF HRAS KRAS LPAR4 NTRK3
17 pigmentation MP:0001186 9.65 ALK BRAF KRAS NRAS NTRK1
18 skeleton MP:0005390 9.61 ALK BRAF GOLGA5 HRAS KRAS LPAR4
19 vision/eye MP:0005391 9.23 ALK BRAF KRAS NRAS NTRK1 NTRK3

Drugs & Therapeutics for Differentiated Thyroid Carcinoma

Drugs for Differentiated Thyroid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 72)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Hormones Phase 3
2 Hormone Antagonists Phase 3
3 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
4
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616 46835353
5
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
6
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
7
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
8
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
9
Lithium carbonate Approved Phase 2 554-13-2
10
Lenvatinib Approved, Investigational Phase 2 417716-92-8
11
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
12
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
13
nivolumab Approved Phase 2 946414-94-4
14
Ipilimumab Approved Phase 2 477202-00-9
15
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
16
Iodine Approved, Investigational Phase 2 7553-56-2 807
17
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
18
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
19 Antioxidants Phase 2
20 Alpha-lipoic Acid Phase 2
21 Vitamins Phase 2
22 Vitamin B9 Phase 2
23 Protective Agents Phase 2
24 Vitamin B Complex Phase 2
25 Folate Phase 2
26 Thioctic Acid Phase 2
27 Antifungal Agents Phase 2
28 Immunosuppressive Agents Phase 2
29 Immunologic Factors Phase 2
30 Fluorodeoxyglucose F18 Phase 2
31 Radiopharmaceuticals Phase 2
32 Analgesics Phase 2
33 Anti-Inflammatory Agents Phase 2
34 Analgesics, Non-Narcotic Phase 2
35 Cyclooxygenase 2 Inhibitors Phase 2
36 Anti-Inflammatory Agents, Non-Steroidal Phase 2
37 Peripheral Nervous System Agents Phase 2
38 Antirheumatic Agents Phase 2
39 Cyclooxygenase Inhibitors Phase 2
40 Mitogens Phase 2
41 Fluorides Phase 2
42 Deoxyglucose Phase 2
43 Endothelial Growth Factors Phase 2
44 Tranquilizing Agents Phase 2
45 Central Nervous System Depressants Phase 2
46 Antidepressive Agents Phase 2
47 Psychotropic Drugs Phase 2
48 Antimanic Agents Phase 2
49
Apatinib Phase 2 811803-05-1
50
Liposomal doxorubicin Phase 2 31703

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 Total Thyroidectomy With Harmonic Scalpel® Versus Standard Surgery. Open Multicentric Randomized Controlled Trial Unknown status NCT00385983 Phase 4
2 Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients - Estimabl Unknown status NCT00435851 Phase 3 Thyrogen, thyroid hormone withdrawal, iode 131
3 Phase 3 Trial of Adjuvant External Beam Radiotherapy for Locally Invasive Differentiated Thyroid Carcinoma Completed NCT00144079 Phase 3
4 Clinical Trial to Evaluate Efficacy of Redifferentiation Therapy Using Alpha-lipoic Acid in Thyroid Cancer Patients With Decreased Radioactive Iodine Uptake Unknown status NCT01396733 Phase 2 alpha-lipoic acids
5 A Phase II Study to Investigate the Efficacy of RAD001 (Afinitor®, Everolimus) in Patients With Irresectable Recurrent or Metastatic Differentiated, Undifferentiated (Anaplastic) and Medullary Thyroid Carcinoma Unknown status NCT01118065 Phase 2 everolimus
6 Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation Completed NCT00519896 Phase 2 sunitinib malate
7 Phase II Study Of Celecoxib In Metastatic Differentiated Thyroid Carcinoma Completed NCT00061906 Phase 2 celecoxib
8 Preliminary Study of the Interest of Diffusion-weighted Magnetic Resonance Imaging in the Early Detection of Differentiated Thyroid Carcinoma Cervical Recurrence. Comparison with18F-FDG PET/CT Completed NCT02515084 Phase 2
9 Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy Completed NCT01811212 Phase 2 Cabozantinib S-malate
10 A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma Completed NCT00118248 Phase 2 tanespimycin
11 A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma Completed NCT00104871 Phase 2 Bortezomib
12 A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma Completed NCT01813136 Phase 2 Continuous pazopanib (Arm A);Intermittent pazopanib (Arm B)
13 Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma Completed NCT00887107 Phase 2 Sorafenib (nexavar)
14 A Phase II Study of External Beam Radiotherapy for Locoregionally Advanced or Recurrent Differentiated Thyroid Carcinoma Completed NCT01173289 Phase 2
15 A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy Completed NCT00729157 Phase 2
16 The Effects of Lithium Carbonate on Low Dose Radioiodine Ablation in Early Thyroid Cancer Treatment Completed NCT00251316 Phase 2 Lithium Carbonate;Placebo
17 Phase 2 of Sunitinib (Sutent) in Patients With Locally Advanced or Metastatic Anaplastic, Differentiated or Medullar Thyroid Cancer Completed NCT00510640 Phase 2 Sunitinib
18 A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer Recruiting NCT03506048 Phase 2 Lenvatinib
19 The Effectiveness and Safety of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma: a Phase 2 Trial. Recruiting NCT03167385 Phase 2 Apatinib Mesylate
20 A Prospective, Multicenter, Open Label Phase Ⅱ Clinical Trial of Doxorubicin Hydrochloride Liposome Injection Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma Recruiting NCT03387943 Phase 2 PLD;Cisplatin
21 A Multi-center , Opened, Phase II Study of Safety and Efficacy of Sulfatinib in Advanced Medullary Thyroid Carcinoma ( MTC) and Iodine-refractory Differentiated Thyroid Carcinoma (DTC) Recruiting NCT02614495 Phase 2 Surufatinib
22 Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy Recruiting NCT03914300 Phase 2 Cabozantinib;Cabozantinib S-malate
23 A Randomized, Double Blind, Placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Vandetanib (ZD6474) in Patients With Locally Advanced or Metastatic Papillary or Follicular Thyroid Carcinoma Failing or Unsuitable for Radioiodine Therapy Active, not recruiting NCT00537095 Phase 2 Vandetanib
24 A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting Active, not recruiting NCT02041260 Phase 2 Cabozantinib
25 Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers Active, not recruiting NCT00381641 Phase 2 Sunitinib;Sunitinib Malate
26 Sorafenib in Patients With Hepatopulmonary Syndrome: A Double-Blind Randomized Clinical Trial Terminated NCT02021929 Phase 2 Sorafenib;Placebo
27 A Phase I Study of Cyclotron-produced Tc-99m Pertechnetate (CPERT) in Patients With Thyroid Cancer Completed NCT01437254 Phase 1 CPERT;GPERT
28 A Phase I Clinical Trial of Pazopanib in Combination With Escalating Doses of Radioactive 131I in Patients With Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake Completed NCT01413113 Phase 1 pazopanib hydrochloride
29 Cognitive Functions and Mood During Thyrotropin Suppressive Therapy in Patients With Differentiated Thyroid Carcinoma Unknown status NCT02665325 TSH-suppressive therapy
30 Lacrimal Drainage System Obstruction Associated to Radioactive Iodine Therapy for Thyroid Carcinoma Unknown status NCT01579344 Radioiodine therapy
31 Effectiveness of [124I]-PET/CT and [18F]-FDG-PET/CT for Localizing Recurrence in Patients With Differentiated Thyroid Carcinoma Who Have Elevated Serum Thyroglobulin Levels But Are Tumor-negative on Conventional Imaging Studies Unknown status NCT01374659
32 Brown Adipose Tissue Activity and Thyroid Hormone Completed NCT02499471
33 A Study to Evaluate and Compare the Surgical Outcomes, Aesthetic Effects and Incision Length of Different Access Procedures in Patients With DTC Completed NCT03239769
34 Clinical Evaluation of a New Highly Sensitive Thyroglobulin Assay in Differentiated Thyroid Carcinoma Completed NCT00148213
35 Is the Thyroglobulin Measurement Under Thyroxine of Prognostic Value Before rhTSH-Aided Radioiodine Ablation in Differentiated Thyroid Carcinoma? Completed NCT00439127
36 Recombinant Human TSH (rhTSH)-Aided Radioiodine (131) Therapy for Thyroid Remnant Ablation in Differentiated Thyroid Cancer Patients: a Comparison Between 1850 MBq and 3700 MBq Activities Completed NCT00454077
37 Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436 Completed NCT01534897 GSK2118436
38 Post-Marketing Surveillance of Lenvima in Korean Patients Recruiting NCT02764554
39 Drug Use Investigation of Sorafenib/ NEXAVAR® for Unresectable Differentiated Thyroid Carcinoma (DTC) Recruiting NCT02185560 Sorafenib (Nexavar, BAY43-9006)
40 Significance of Single Center, Open and Prospective Evaluation of Contralateral Central Lymph Node Dissection in Unilateral cN0 Differentiated Thyroid Carcinoma. Recruiting NCT03845647
41 Relationship Between Estimated Glomerular Filtration Rate and Biological Half-life of 131I. Prospective Analysis in Patients With Differentiated Thyroid Carcinoma. Recruiting NCT02773667
42 Clinical Evaluation of a I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer Using PROBE Design Recruiting NCT01704586
43 Distinct Shifts in the Microbiota Are Associated With Iodine-131 Therapy and Hypothyroidism Recruiting NCT03574051 Early Phase 1 Probiotic
44 RIFTOS MKI - Radioactive Iodine reFractory Asymptomatic Patients in Differentiated Thyroid Cancer - an Observational Study to Assess the Use of Multikinase Inhibitors Active, not recruiting NCT02303444 Sorafenib (Nexavar, BAY43-9006);Other Multikinase inhibitors
45 Randomized Controlled Trial Evaluating Use of Arista Absorbable Surgical Hemostatic Powder in Total Thyroidectomy With and Without Neck Dissections Withdrawn NCT02568085

Search NIH Clinical Center for Differentiated Thyroid Carcinoma

Genetic Tests for Differentiated Thyroid Carcinoma

Anatomical Context for Differentiated Thyroid Carcinoma

MalaCards organs/tissues related to Differentiated Thyroid Carcinoma:

41
Thyroid, Lymph Node, Bone, Lung, Testes, Salivary Gland, Brain

Publications for Differentiated Thyroid Carcinoma

Articles related to Differentiated Thyroid Carcinoma:

(show top 50) (show all 3037)
# Title Authors PMID Year
1
Codon-specific translation reprogramming promotes resistance to targeted therapy. 71
29925953 2018
2
A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. 71
28854169 2017
3
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. 71
25079330 2014
4
Copper is required for oncogenic BRAF signalling and tumorigenesis. 71
24717435 2014
5
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. 71
24670642 2014
6
Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. 71
24512911 2014
7
A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. 71
23685455 2013
8
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. 71
23302800 2013
9
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. 71
22281684 2012
10
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). 71
22113612 2011
11
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. 71
21107320 2010
12
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. 71
21107323 2010
13
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. 71
20823850 2010
14
Inhibition of mutated, activated BRAF in metastatic melanoma. 71
20818844 2010
15
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. 71
18398503 2008
16
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. 71
17785355 2007
17
BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. 71
17488796 2007
18
BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. 71
17374713 2007
19
Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. 71
16772349 2006
20
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. 71
16174717 2005
21
High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. 71
15998781 2005
22
BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. 71
16015629 2005
23
High incidence of thyroid cancer in long-standing goiters with thyroglobulin mutations. 71
16187918 2005
24
Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. 71
15841082 2005
25
Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. 71
15687339 2005
26
Mutations of BRAF and RAS are rare events in germ cell tumours. 71
15386408 2005
27
Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. 71
15356022 2004
28
BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. 71
15342696 2004
29
Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. 71
15181070 2004
30
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. 71
15126572 2004
31
BRAF T1796A transversion mutation in various thyroid neoplasms. 71
15001635 2004
32
Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. 71
14513361 2003
33
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. 71
14602780 2003
34
Exclusion of BRAFV599E as a melanoma susceptibility mutation. 71
12794760 2003
35
BRAF mutations in metastatic melanoma: a possible association with clinical outcome. 71
12960123 2003
36
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. 71
12670889 2003
37
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. 71
12644542 2003
38
Absence of exon 15 BRAF germline mutations in familial melanoma. 71
12619120 2003
39
High frequency of BRAF mutations in nevi. 71
12447372 2003
40
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. 71
12198537 2002
41
Mutations of the BRAF gene in human cancer. 71
12068308 2002
42
Ultrasound characteristics of thyroid nodules facilitate interpretation of the malignant risk of Bethesda system III/IV thyroid nodules and inform therapeutic schedule. 38
31211509 2019
43
Prognostic Impact of the Turin Criteria in Poorly Differentiated Thyroid Carcinoma. 38
31098668 2019
44
Long-term disease control and high clinical benefit in a patient with advanced thyroid cancer treated with lenvatinib. 38
31385526 2019
45
Epithelial-to-mesenchymal transition in thyroid cancer: a comprehensive review. 38
31378850 2019
46
Microscopically positive surgical margins and local recurrence in thyroid cancer. A meta-analysis. 38
30795955 2019
47
Prognostic Significance of Extent of Invasion in Poorly Differentiated Thyroid Carcinoma. 38
31397224 2019
48
Efficacy and safety of lenvatinib in an elderly patient with metastatic papillary thyroid carcinoma and cardiological comorbidity: a case report. 38
31393171 2019
49
PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH N1B PAPILLARY THYROID CARCINOMA. 38
31013158 2019
50
Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma. 38
31298630 2019

Variations for Differentiated Thyroid Carcinoma

ClinVar genetic disease variations for Differentiated Thyroid Carcinoma:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 BRAF NM_004333.6(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 7:140453136-140453136 7:140753336-140753336
2 LIG4 NM_002312.3(LIG4): c.1673A> C (p.Gln558Pro) single nucleotide variant Likely pathogenic 13:108861944-108861944 13:108209596-108209596
3 CDH1 NM_004360.5(CDH1): c.2351G> C (p.Arg784Pro) single nucleotide variant Uncertain significance 16:68863612-68863612 16:68829709-68829709
4 RUNX1 NM_001754.4(RUNX1): c.749G> A (p.Arg250His) single nucleotide variant Uncertain significance rs771614642 21:36206763-36206763 21:34834466-34834466
5 PALB2 NM_024675.3(PALB2): c.2147A> G (p.Asn716Ser) single nucleotide variant Uncertain significance rs148335539 16:23641328-23641328 16:23630007-23630007
6 MSH2 NM_000251.2(MSH2): c.1706A> G (p.Glu569Gly) single nucleotide variant Uncertain significance rs786201077 2:47698148-47698148 2:47471009-47471009

Expression for Differentiated Thyroid Carcinoma

Search GEO for disease gene expression data for Differentiated Thyroid Carcinoma.

Pathways for Differentiated Thyroid Carcinoma

Pathways related to Differentiated Thyroid Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.28 NTRK3 NTRK1 NRAS KRAS HRAS BRAF
2
Show member pathways
13.08 NTRK3 NTRK1 NRAS KRAS HRAS BRAF
3
Show member pathways
13.06 NTRK3 NTRK1 NRAS KRAS HRAS ALK
4
Show member pathways
12.89 NRAS NCOA4 KRAS HRAS BRAF
5
Show member pathways
12.87 NTRK3 NTRK1 NRAS KRAS HRAS BRAF
6
Show member pathways
12.82 NRAS KRAS HRAS EIF1AX BRAF
7
Show member pathways
12.82 PPARG NRAS KRAS HRAS BRAF
8 12.78 NTRK1 NRAS KRAS HRAS BRAF
9
Show member pathways
12.73 NTRK1 NRAS LPAR4 KRAS HRAS BRAF
10
Show member pathways
12.71 NRAS KRAS HRAS BRAF ALK
11
Show member pathways
12.71 NTRK3 NTRK1 NRAS KRAS HRAS BRAF
12 12.64 NRAS LPAR4 KRAS HRAS BRAF
13
Show member pathways
12.59 NRAS KRAS HRAS BRAF
14
Show member pathways
12.52 NRAS KRAS HRAS BRAF
15
Show member pathways
12.5 NRAS KRAS HRAS BRAF
16
Show member pathways
12.45 NTRK3 NTRK1 NRAS KRAS HRAS
17
Show member pathways
12.42 NRAS KRAS HRAS BRAF
18
Show member pathways
12.41 NRAS LPAR4 KRAS HRAS
19
Show member pathways
12.41 NRAS KRAS HRAS BRAF
20
Show member pathways
12.4 RET PPARG PAX8 NTRK1 NRAS NCOA4
21
Show member pathways
12.35 NRAS KRAS HRAS BRAF
22 12.31 NRAS KRAS HRAS BRAF
23
Show member pathways
12.3 NRAS KRAS HRAS BRAF
24
Show member pathways
12.3 NTRK3 NTRK1 NRAS KRAS HRAS BRAF
25
Show member pathways
12.28 NRAS KRAS HRAS BRAF
26 12.26 PPARG PAX8 NTRK1 ETV6
27
Show member pathways
12.24 PPARG NRAS KRAS HRAS BRAF
28
Show member pathways
12.21 RET NRAS KRAS HRAS
29
Show member pathways
12.2 NRAS KRAS HRAS BRAF
30 12.19 NDUFA13 KRAS HRAS BRAF
31
Show member pathways
12.15 PPARG NRAS KRAS HRAS
32
Show member pathways
12.13 PPARG NRAS KRAS HRAS BRAF
33 12.12 NTRK3 NTRK1 NRAS KRAS HRAS
34 12.12 RET PPARG PAX8 NTRK1 NRAS NCOA4
35
Show member pathways
12.1 NRAS KRAS HRAS BRAF
36
Show member pathways
12.1 NRAS KRAS HRAS BRAF
37
Show member pathways
12.09 NTRK1 NRAS KRAS HRAS BRAF
38
Show member pathways
12.09 NTRK3 NTRK1 NRAS KRAS HRAS BRAF
39 12.02 NRAS KRAS HRAS BRAF
40 12 NRAS KRAS HRAS BRAF
41 11.98 NRAS KRAS HRAS BRAF
42
Show member pathways
11.95 NRAS KRAS HRAS
43 11.91 NRAS KRAS HRAS
44 11.89 PPARG KRAS BRAF
45
Show member pathways
11.86 NRAS KRAS HRAS
46 11.84 NRAS KRAS HRAS
47 11.74 NRAS KRAS HRAS BRAF
48 11.72 PAX8 HRAS BRAF
49 11.69 NRAS KRAS HRAS
50
Show member pathways
11.67 NRAS KRAS HRAS BRAF

GO Terms for Differentiated Thyroid Carcinoma

Cellular components related to Differentiated Thyroid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 8.92 RET NTRK3 NTRK1 ALK

Biological processes related to Differentiated Thyroid Carcinoma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.96 RET NTRK3 KRAS HRAS BRAF
2 cell differentiation GO:0030154 9.87 RET PPARG PAX8 NTRK3 NTRK1 ETV6
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.83 NTRK1 KRAS ERC1 ALK
4 negative regulation of neuron apoptotic process GO:0043524 9.81 NTRK1 KRAS HRAS BRAF
5 positive regulation of MAPK cascade GO:0043410 9.78 RET NTRK3 NTRK1 HRAS
6 MAPK cascade GO:0000165 9.77 RET NRAS KRAS HRAS BRAF
7 ephrin receptor signaling pathway GO:0048013 9.76 NTRK3 NTRK1 HRAS
8 Ras protein signal transduction GO:0007265 9.75 NRAS KRAS HRAS
9 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.74 NRAS KRAS HRAS
10 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.71 RET NTRK3 NTRK1 ALK
11 negative regulation of apoptotic process GO:0043066 9.67 NTRK1 ERC1 BRAF
12 cellular response to nerve growth factor stimulus GO:1990090 9.63 NTRK3 NTRK1 BRAF
13 positive regulation of phospholipase C activity GO:0010863 9.6 NTRK3 HRAS
14 positive regulation of protein phosphorylation GO:0001934 9.56 NTRK3 NTRK1 KRAS HRAS
15 response to isolation stress GO:0035900 9.55 KRAS HRAS
16 mechanoreceptor differentiation GO:0042490 9.54 NTRK3 NTRK1
17 cellular response to retinoic acid GO:0071300 9.46 RET PPARG NTRK3 NDUFA13
18 neurotrophin signaling pathway GO:0038179 9.43 NTRK3 NTRK1
19 peptidyl-tyrosine phosphorylation GO:0018108 9.35 RET NTRK3 NTRK1 BRAF ALK
20 positive regulation of ERK1 and ERK2 cascade GO:0070374 8.92 NTRK3 NTRK1 HRAS BRAF
21 signal transduction GO:0007165 10.19 RET PPARG NRAS LPAR4 KRAS HRAS

Molecular functions related to Differentiated Thyroid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.8 RET NTRK3 NTRK1 BRAF ALK
2 nucleotide binding GO:0000166 9.72 RET NRAS KRAS HRAS BRAF
3 GPI-linked ephrin receptor activity GO:0005004 9.37 NTRK3 NTRK1
4 protein tyrosine kinase activity GO:0004713 9.35 RET NTRK3 NTRK1 BRAF ALK
5 neurotrophin binding GO:0043121 9.26 NTRK3 NTRK1
6 neurotrophin receptor activity GO:0005030 9.16 NTRK3 NTRK1
7 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.92 RET NTRK3 NTRK1 ALK

Sources for Differentiated Thyroid Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....